Micropoint Biotechnologies Co., Ltd, established in 2007 and headquartered in Shenzhen China, has been committing to providing medical professionals and patients with rapid point-of-care diagnostics and self-test products and solutions that can enhance quality of care while increasing patient quality of life. We now have developed 100+ distribution partners among all over the word.
From our earliest days, we launched the MEMS (Micro-Electro-Mechanical System: qLabs- monitoring system for warfarin anti-coagulated therapy. After several revolutions in recent years, the qLabs family can achieve a cost-effective and quality stable way to combination several market trends in anti-coagulation fields.
Based on microfluidic (Lab-on-a-chip) technology, we have strong expertise in cardiovascular disease diagnostics and assessment, including heart failure, myocardial infarctions, and embolisms. We provide a range of tests for anticoagulants used in stroke, heart attack and venous thromboembolisms, including deep vein thrombosis (DVT) and pulmonary embolisms (PE). Our tests for sepsis and severe systemic bacterial infections enable medical teams to differentiate between infection types.
In the further, Micropoint will keep on seeking to develop innovative products and solutions that can quickly and reliably provide data that support medical decision-making, from hospital or home.